Aardvark Therapeutics Announces FDA Orphan Drug Designation Granted to ARD-101, a Novel Drug Candidate for Prader-Willi Syndrome

  • The FDA granted Aardvark Therapeutics a Rare Pediatric Designation for the use of ARD-101 in Prader-Willi Syndrome (PWS), a rare genetic disease characterized by extreme and unabating hunger.
  • Aardvark’s Phase 2 trial of oral ARD-101 in young adults with PWS is now open for enrollment of additional subjects.

Click here to view the full article (external link)